#United States #Menlo Park #Apreo Health #BREATHE Airway Scaffold #Emphysema Treatment

Apreo Health's Strategic Advancements

Apreo Health, a pioneering company in the realm of medical devices focusing on severe emphysema treatment, has entered a significant phase of development by welcoming David Amerson to its Board of Directors. This addition is coupled with a strategic investment from OSF Ventures, which aims to consolidate the company's financial backing while preparing for a major presence at the upcoming American Thoracic Society (ATS) 2026 International Conference in Orlando, Florida.

A Transformative Leadership Addition

David Amerson brings over 30 years of experience in the medical device field, renowned for his leadership roles across various successful enterprises. Most notably, he held the position of President of Interventional Urology at Teleflex, where he played an instrumental role in the acquisition of NeoTract. Under his guidance, NeoTract’s UroLift® System achieved recognition as an industry standard. His vast experience will be invaluable as Apreo Health seeks to revolutionize treatment methodologies for emphysema.

In a statement, CEO Karun Naga affirmed, "We are at a pivotal moment as we scale our clinical evidence and prepare for the next phase of commercial readiness. Dave Amerson's track record of scaling transformative medical technologies is unparalleled. His support, alongside OSF Ventures, further endorses the potential of the BREATHE Airway Scaffold to enhance treatment outcomes for the large number of patients suffering from emphysema."

Funding From OSF Ventures

The investment from OSF Ventures is particularly significant, illustrating a growing recognition of Apreo Health’s innovative technology within expansive healthcare systems. OSF is focused on identifying technologies capable of redefining chronic disease management trajectories. Liridon Rrushaj, Director of Venture Investing at OSF Ventures, emphasized, "Apreo's minimally invasive approach aligns with our goal of supporting innovations that simplify the patient pathway while delivering measurable clinical improvements."

Upcoming Presentation at ATS 2026

Apreo Health will showcase new clinical data during a scientific session at ATS 2026, set to occur from May 15-20, 2026. This presentation aims to highlight the sustained physiological impact of the BREATHE Airway Scaffold, further bolstering the foundational research previously published in the American Journal of Respiratory and Critical Care Medicine. Interested attendees are invited to join Apreo Health on May 20th at 12 p.m. EDT at room W224 AB/EF (Level II, OCCC West Concourse).

About Apreo Health

As a clinical-stage medical device company, Apreo Health is reimagining intervention methodologies for severe emphysema. The company’s BREATHE Airway Scaffold is designed to provide a tissue-sparing treatment approach, expanding access to effective care by overcoming barriers set by traditional interventional options. Notably, the Apreo BREATHE Airway Scaffold remains an investigational device, intended exclusively for clinical investigations under U.S. law.

For further details, visit www.apreohealth.com.

The Apreo BREATHE Airway Scaffold is an Investigational Device. Limited by United States law to investigational use. Exclusively for clinical investigation. ©2026 Apreo Health, Inc. All rights reserved. Apreo and Apreo Health are registered trademarks of Apreo Health, Inc.